4-Hydroxy-N-propyl-N-isopropyltryptamine (4-HO-PiPT, Piprocin) is a substituted tryptamine derivative which is claimed to have psychedelic effects.[1] It acts as a 5-HT2A receptor agonist, with an EC50 of 13.8 nM and an efficacy of 104.8% (vs 5-HT),[2] and has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada.[3]
Identifiers | |
---|---|
| |
PubChem CID | |
Chemical and physical data | |
Formula | C16H24N2O |
Molar mass | 260.381 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Morrison J. Glycosylated psilocin derivatives and methods of use. WO 2024/042239A1
- ^ Banister S, Jorgensen W, Jinlong T. Compounds. Patent WO 2023/115167
- ^ Knill A, Tobias S, Matthews J, Ti L (June 2022). A Report on British Columbia's Unregulated Drug Supply. Drug checking trends across British Columbia, January to December 2021 (PDF). British Columbia Centre on Substance Use (Report).